

# **Retinoblastoma Genetic Testing**

Document Number: GGPCR-00.037 Revision Number: 1.03

Document Type: Guideline Effective Date: 7/28/2022 4:38:11 PM

Location: 3. APL Folder Structure\Genetics and Genomics (GG)\GG Provincial Program Documents (GGP)\GG

Program Client Resources (CR)

# **Retinoblastoma Genetic Testing**

# **APPLICABILITY**

This document applies to all healthcare providers who are ordering retinoblastoma genetic testing for an Alberta patient.

#### **PURPOSE**

This guideline provides information regarding when retinoblastoma genetic testing should be performed at a facility outside Alberta.

#### **GUIDELINE**

Retinoblastoma genetic testing may be performed at a facility outside Alberta in the following situations:

- 1. Tumor specimen testing genetic testing of RB1 tumor tissue is not presently offered in Alberta
- 2. Proband testing (tumor and/or blood specimen) when the patient is being treated at the Hospital for Sick Children in Ontario
- 3. Clinically indicated rush testing in which the Genetics & Genomics South Molecular Genetics Lab (MGL) is unable to complete testing within the required turn-around-time
  - a. Expedited proband testing (blood specimen) can be completed within 4 weeks at MGL
  - b. Expedited targeted testing for a familial variant can be completed within 2 weeks at MGL providing a locus-specific assay has been developed in advance (MGL must be notified minimally 3 weeks in advance of commencing testing to order locus-specific reagents and ensure functionality).

Funding for out-of-province testing will be provided through the Genetic Resource Centre.

For all other indications, retinoblastoma genetic testing will be performed at MGL in Alberta. Testing situations include:

- 1. Proband testing (blood specimen) when the patient is Alberta Health-insured and not undergoing treatment in Ontario at the time of testing
- 2. Familial testing (including prenatal diagnosis) for a known pathogenic variant
  - a. It is the responsibility of the ordering healthcare provider to coordinate collection of a positive control specimen if DNA is not banked at MGL

### RESPONSIBILITY

Ordering healthcare providers and Genetics & Genomics personnel are responsible for implementing this guideline.

Page 1 of 1 APL WEB